Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30473425 | 0.82 | — | — | |
| SCHEMBL14732897 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNAHTTTDP1KDM4E | |
| SCHEMBL904673 | 0.82 | — | — | |
| Methane SCHEMBL8177743 | 0.80 | ALDH1A1 (0.47) | ALDH1A1LMNAHTTTDP1KDM4E | |
| SCHEMBL904409 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTTDP1KDM4E | |
| SCHEMBL2552339 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTTDP1KDM4E | |
| SCHEMBL2952828 | 0.76 | SLC2A1 (0.53) | ALDH1A1LMNAHTTTDP1KDM4E | |
| SCHEMBL5234381 | 0.75 | KCNH2 (0.46) | ALDH1A1LMNAHTTTDP1KDM4E | |
| SCHEMBL904632 | 0.75 | — | — | |
| SCHEMBL9602287 | 0.74 | HSD17B10 (0.47) | ALDH1A1TDP1KDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445685-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8173816-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2012-05-08 | — | — | US | disclosed |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-29 | — | — | US | disclosed |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2011-01-27 | — | — | US | disclosed |
| US-7863300-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-7671207-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2010-03-02 | — | — | US | disclosed |
| US-7465801-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | ALDH1A1 742/4885LMNA 2841/4885HTT 2193/4885 |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | ALDH1A1 1084/4885LMNA 2601/4885HTT 2409/4885 |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | ALDH1A1 1084/4885LMNA 2601/4885HTT 2409/4885 |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | ALDH1A1 1084/4885LMNA 2601/4885HTT 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.